The Taibo® Sildenafil Citrate Orally Disintegrating Tablets (50mg), which is our company's new dosage form and deemed to have passed the consistency evaluation, was recently approved for marketing.
MoreRecently, the management of C&O has accepted an invitation from Meiji Seika Kaisha, Ltd. to visit the top management in Japan. With the common goal of fostering closer working relationships, the two sides discussed ways to further strengthen strategi
MoreA new prescription drug launched by C&O - pantoprazole sodium enteric-coated capsules - has a manufacturing technology patent from the State Intellectual Property Office and is included in the National Medical insurance Drugs Catalogue (Category B).
MoreThe environmentally friendly R&D center in Pudong, Shanghai, covering a floor area of more than 2,400 m2, will focus on the development of innovative drugs such as anti-infective, anti-diabetic, anti-tumor, anti-obesity, and peptide drugs.
MoreC&O is committed to the pursuit of the highest quality, and superior production capabilities, Nanjing Chang Ao Pharmaceutical Co., Limited was awarded the title of “technology-intensive and knowledge-intensive enterprise” by the Department of Science
More
Address5/F, Jihao Building, 1086 Shennan East Road, Luohu District, Shenzhen
Adverse drug reactions / Event feedback hotline025-6816 1304
Adverse drug reactions / Event feedback mailGVP@changao.com
Official WeChat account 
Mobile page